A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis

Keyphrases

• Active Lesions 20%
• Adverse Events 20%
• Adverse Events of Special Interest 20%
• Anti-inflammatory Activity 20%
• Antipruritic Effect 20%
• Assessment Score 20%
• Atopic Dermatitis 40%
• Body Surface Area 60%
• Cardiovascular Thrombosis 20%
• Extensive Disease 20%
• Half Maximal Inhibitory Concentration 20%
• Investigator's Global Assessment 40%
• Janus 20%
• Life Safety 20%
• Major Adverse Cardiovascular Events 20%
• Malignancy 20%
• Moderate-to-severe Atopic Dermatitis 100%
• Myelosuppression 20%
• Patient-reported Outcomes 20%
• Pharmacokinetic Parameters 20%
• Pharmacokinetics 20%
• Phase II Study 20%
• Quality of Life 40%
• Quality of Life Assessment 20%
• Ruxolitinib Cream 100%
• Serious Infection 20%
• Steady-state Plasma Concentration 20%
• Tolerability 20%
• Treatment-related Adverse Events 20%
• Twice Daily 20%
• Use Conditions 20%
• Use Period 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 60%
• Anti-Inflammatory Drug 20%
• Antipruritic Agent 20%
• Atopic Dermatitis 100%
• Bone Marrow Suppression 20%
• Cardiovascular Disease 20%
• Diseases 20%
• IC50 20%
• Infection 20%
• Pharmacokinetic Parameter 20%
• Pharmacokinetics 20%
• Ruxolitinib 100%
• Thrombosis 20%
• Tolerability 20%